        |
|
 |
 |
|||||||||
|
|||||||||
|
Advisory board
Robert J Kavlock, Ph.D.
Dr. Robert J Kavlock is the Director of EPAs National Center for Computational Toxicology (NCCT), a position he has held since the founding of the NCCT in 2005. The mission of the NCCT is to provide improved hazard and risk identification for assessment of environmental chemicals through the blending of advances in modern molecular biology with computational sciences. The NCCT is developing a number of high throughput decision support tools including ToxCast, ToxRefDB and ACToR. Prior to that time he spent 15 years as the Director of the Reproductive Toxicology Division in EPAs Office of Research. In 2007 he was the recipient of ORDs Statesmen of the Year Award. He has published more than 200 scientific papers, 16 book chapters, and edited three books, including a co-editor of the Global Assessment of the State-of-the-Science of Endocrine Disruptors (WHO, 2002). He is a past president of the Teratology Society and is active in the Society of Toxicology. He is a member of the editorial boards of Environmental Health Perspectives, the Journal of Toxicology and Environmental Health, and Birth Defects Part B: Developmental and Reproductive Toxicity.
Markku Pasanen, Prof.
Prof. Markku Pasanen has 30 years experience in studies on human foeto-placental steroid- and xenobiotic-metabolizing enzymes. The other main branch of research has been to study bioactivation of chemicals and the expression and regulation different CYP enzymes in connection of chemical-induced liver injury in different animal models and man. His present position (from 2006-) is professor of medicinal toxicology at the University of Eastern Finland, Faculty of Health Sciences, Kuopio, (Finland); before that for ten years senior medical officer at the National Agency for Medicines, Helsinki (Finland). He is an external non-clinical expert of the European Medicines Agency (EMA) being nominated as a member in CHMP Scientific Advice (SAWP), Safety (SWP), and Pharmacogenetics (PgWP) working parties.
Darrell R. Abernethy, M.D., Ph.D.
Dr. Darrell R. Abernethy, M.D., Ph.D. is responsible for leading the development of a pharmacological mechanism based safety program in the Office of Clinical Pharmacology to work in synergy with efforts in the Office of Surveillance and Epidemiology and other Offices and Centers at FDA. Dr. Abernethy brings more than 25 years of experience in medicine and pharmacology, including positions in academia, practice and research. Prior to joining FDA he served as Chief Science Officer at USP.